Engineered proteins from transgenic animals

描述（由申请人提供）：生物技术行业正在开发的产品中约有25%是抗体，其中许多抗体直接针对人体细胞和组织的表位。基于蛋白质-蛋白质相互作用的最新进展和转基因技术的最新发展，我们提出了一种具有治疗潜力的抗体生产的新概念。这一概念的实施将避免许多昂贵和耗时的修改，这些修改是在确定潜在治疗性单克隆抗体后经常需要的，以便优化其药理特性并使其适合大规模生产。通过结合来自体外研究的最新数据和对基因组学的初步理解，我们将扩大可访问的表位范围，从而扩大潜在治疗抗体的范围

DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies PUBLIC HEALTH RELEVANCE: During the past 15 years, more than 20 therapeutic antibodies have been developed to treat human disease, particularly in the fields of automimmunity and cancer. We have proposed a novel method to obtain potentially therapeutic antibodies that will recognize targets that cannot be obtained from conventional sources. In addition, the technology will engineer antibodies that have improved pharmacological attributes and better manufacturing properties. This technology will provide a cost-effective route to increasing the range of therapeutic candidates for the treatment of human disease.